

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/679,081
Filing Date	10/3/2003
First Named Inventor	Hans-Michael Dosch
Art Unit	1632
Examiner Name	Lieto
Attorney Docket Number	2560.001

Sheet

2

of

5

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
UPL		S. WINER et al, "ICA69null nonobese diabetic mice develop diabetes, but resist disease acceleration by cyclophosphamide", Journal of Immunology, 168(1):475-482 (January, 2002)	
		S. MARTIN et al, "Autoantibodies to the islet antigen ICA69 occur in IDDM and in rheumatoid arthritis", Diabetologia, 38(3):351-355 (March, 1995)	
		S. WINER et al, "ICA69null NOD congenic mice are protected from sialitis and cyclophosphamide-accelerated diabetes", Diabetes, 50(Supp 2):A503 (June, 2001) Abstract XP008028882, 2114-PO	
		K. YANAGI et al, "Anti-120-kDa alpha-fodrin immune response with Th1-cytokine profile in the NDO mouse model of Sjogren's syndrome", Eur. J. Immunol., 28(10):3336-3345 (October, 1998)	
		S. WINER et al, "Primary Sjogren's syndrome and deficiency of ICA69", The Lancet, 360(9339):1063-1069 (October, 2002)	
		R. FOX et al, "Update in Sjogren syndrome", Current Opinion in Rheumatology, 12:391-398 (2000)	
		J. JAMES et al, "Role of viruses in systemic lupus erythematosus and Sjogren syndrome", Current Opinion in Rheumatology, 13:370-376 (2001)	
		R. FOX et al, "Current issues in the diagnosis and treatment of Sjogren's syndrome", Current Opinion in Rheumatology, 11(5):364-371 (September, 1999)	
		J. HARLEY et al, "Anti-Ro (SS-A) and anti-La (SS-B) in patients with Sjogren's syndrome", Arthritis and Rheumatism, 29(2):196-206 (February, 1986)	
✓		O. BILLAUT-MULOT et al, "SS-56, a novel cellular target of autoantibody responses in Sjogren syndrome and systemic lupus erythematosus", The Journal of Clinical Investigation, 108(6):861-869 (September, 2001)	

Examiner
SignatureDate
Considered

5.26.05

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/679,081
Filing Date	10/3/2003
First Named Inventor	Hans-Michael Dosch
Art Unit	1632
Examiner Name	Lieto
Attorney Docket Number	2560.001

Sheet

3

of

5

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
LDL		N. HANEJI et al, "Identification of alpha-Fodrin as a candidate autoantigen in primary Sjogren's syndrome", Science, 276:604-607 (April, 1997)	
		M. KUWANA et al, "Autoantibodies to the amino-terminal fragment of beta-Fodrin expressed in glandular epithelial cells in patients with Sjogren's syndrome", The Journal of Immunology, 167:5449-5456 (2001)	
		C. ROBINSON et al, "Transfer of human serum IgG to nonobese diabetic Igmu null mice reveals a role for autoantibodies in the loss of secretory function of exocrine tissues in Sjogren's syndrome", Proc. Natl. Acad. Sci. USA, 95:7538-7543 (June, 1998)	
		M. HUMPHREYS-BEHER et al, "Utilization of the non-obese diabetic (NOD) mouse as an animal model for the study of secondary Sjogren's syndrome", Adv. Exp. Med. Biol., 350:631-636 (1994)	
		R. HOFFMAN et al, "Sjogren's syndrome in MRL/l and MRL/n mice", Arthritis and Rheumatism, 27(2):157-165 (February, 1984)	
		N. HANEJI et al, "A new animal model for primary Sjogren's syndrome in NFS/sld mutant mice", The Journal of Immunology, 153:2769-2777 (1994)	
		J. BRAYER et al, "Sjogren's syndrome: immunological response underlying the disease", Arch. Immunol. Ther. Exp., 49:353-360 (2001)	
		C. ROBINSON et al, "A novel NOD-derived murine model of primary Sjogren's syndrome", Arthritis & Rheumatism, 41(1):150-156 (January, 1998)	
		W. KARGES et al, "Loss of self-tolerance to ICA69 in nonobese diabetic mice", Diabetes, 46:1548-1556 (October, 1997)	
		H.-MICHAEL DOSCH et al, "Persistent T cell anergy in human type 1 diabetes", The Journal of Immunology, 163:6933-6940 (1999)	

Examiner Signature	Date Considered
	5.26.05

*EXAMINER: Initial reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/679,081
Filing Date	10/3/2003
First Named Inventor	Hans-Michael Dosch
Art Unit	1632
Examiner Name	
Attorney Docket Number	2560.001

Sheet

4

of

5

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
LX		M. PILON et al, "The diabetes autoantigen ICA69 and its Caenorhabditis elegans homologue, ric-19, are conserved regulators of neuroendocrine secretion", Molecular Biology of the Cell, 11:3277-3288 (October, 2000)	
		S. WINER et al, "ICA69 null nonobese diabetic mice develop diabetes, but resist disease acceleration by cyclophosphamide", The Journal of Immunology, 168:475-482 (2002)	
		W. KARGES et al, "Gene expression of islet cell antigen p69 in human, mouse, and rat", Diabetes, 45:513-521 (April, 1996)	
		S. WINER et al, "Type I diabetes and multiple sclerosis patients target islet plus central nervous system autoantigens; nonimmunized nonobese diabetic mice can develop autoimmune encephalitis", The Journal of Immunology, 166:2831-2841 (2001)	
		D. SERREZE et al, "B lymphocytes are essential for the initiation of T cell-mediated autoimmune diabetes: analysis of a new 'speed congenic' stock of NOD.Igmu null mice", J. Exp. Med., 184:2049-2053 (November, 1996)	
		S. WINER et al, "Peptide dose, MHC affinity, and target self-antigen expression are critical for effective immunotherapy of nonobese diabetic mouse prediabetes", The Journal of Immunology, 165:4086-4094 (2000)	
		H.-M. DOSCH et al, "Measurement of T-cell autoreactivity in autoimmune diabetes", Diabetologia, 43:386-387 (2000)	
		R. HUNGER et al, "Male gonadal environment paradoxically promotes dacryoadenitis in nonobese diabetic mice", J. Clin. Invest., 101(6):1300-1309 (March, 1998)	
		W. CHEN et al, "Evidence that a peptide spanning the B-C junction of proinsulin is an early autoantigen epitope in the pathogenesis of type 1 diabetes", The Journal of Immunology, 167:4926-4935 (2001)	
		C. LAFITTE et al, "Neurological complications of primary Sjogren's syndrome", Journal of Neurology, 248(7):577-584 (July, 2001)	

Examiner
SignatureDate
Considered

6/6/05

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/679,081
				Filing Date	10/3/2003
				First Named Inventor	Hans-Michael Dosch
				Art Unit	1632
				Examiner Name	
Sheet	5	of	5	Attorney Docket Number	2560.001

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
LX		A. ANDONOPOULOS et al, "The spectrum of neurological involvement in Sjogren's syndrome", The British Journal of Rheumatology, 29:21-23 (1990)	
		K. MALINOW et al, "Subacute sensory neuropathy secondary to dorsal root ganglionitis in primary Sjogren's syndrome", Ann. Neurol., 20:535-537 (1986)	
		T. CHUSED et al, "Sjogren's syndrome association with HLA-Dw3", N. Engl. J. Med., 296(16):895-897 (April, 1977)	
		H. FOSTER et al, "Linkage studies of HLA and primary Sjogren's syndrome in multicase families", Arthritis and Rheumatism, 36(4):473-484 (April, 1993)	
		E. GOILLOT et al, "Sialadenitis in nonobese diabetic mice: transfer into syngeneic healthy neonates by splenic T lymphocytes", Clin. Immunol. Immunopathol., 59:462-473 (1991)	
		K. YANAGI et al, "Anti-120-kDa alpha-fodrin immune response with Th1-cytokine profile in the NDO mouse model of Sjogren's syndrome", Eur. J. Immunol., 28:3336-3345 (1998)	
		R. MASAGO et al, "Elevated Proapoptotic Bax and Caspase 3 activation in the NOD.scid model of Sjogren's syndrome", Arthritis & Rheumatism, 44(3):693-702 (March, 2001)	
		C. ROBINSON et al, "Genetically programmed development of salivary gland abnormalities in the NOD (nonobese diabetic)-scid mouse in the absence of detectable lymphocytic infiltration: a potential trigger for sialoadentitis of NOD mice", Clin. Immunol. Immunopathol., 79(1):50-59 (April, 1996)	
✓		J. GROOM et al, "Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjogren's syndrome", The Journal of Clinical Investigation, 109(1):59-68 (January, 2002)	

Examiner Signature		Date Considered	606-05
--------------------	---	-----------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.